The present invention refers to compounds, and to pharmaceutical compositions containing said compounds, of the following formula (I) or a pharmaceutically acceptable salt thereof:including any stereochemically isomeric form thereof, wherein:R1 is independently selected from the group consisting of aliphatic, aromatic or heteroaromatic ring, optionally substituted by one or more substituents chosen from the group consisting of C1-C4 alkyl optionally substituted by one or more halogen atom(s), halogen, C1-C4 alkoxyR2 is independently selected from the group consisting of aliphatic, heteroaliphatic, aromatic or heteroaromatic ring, bicyclic aliphatic, heteroaromatic or aromatic ring, C1-C6 alkyl, alkenyl or alkynyl chain, optionally substituted by one or more substituents chosen from the group consisting of C1-C4 alkyl optionally substituted by one or more halogen atom(s), halogen, C1-C4 alkoxy, cyano, C1-C4 alkylthio, SO-C1-C4 alkyl, SO2-C1-C4 alkyl, N(C1-C4 alkyl)2n is 0, 1 or 2R3 and R4 can be, independently, -H, -F, C1-C4 alkyl, -OH, -OC1-C4 alkylX is O, S, CH2, CH-C1-C4 alkyl, -NH or -NC1-C4 alkylR5 is -H or -CH3 optionally substituted by one or more fluorine atoms.The compounds of the invention can be used in treatment of conditions or diseases mediated by P2X7 receptor.
